Celgene, Genentech, AbbVie, J&J, Roche sales and marketing update

NHS England dropped or restricted coverage of 17 additional drugs covering 25 indications from its list of therapies covered by the Cancer Drugs Fund (CDF). Eight drugs were cut altogether, while nine had the number of reimbursed indications reduced.

Among the drugs completely removed from the list were Kadcyla trastuzumab emtansine from Roche’s Genentech unit to treat second-line metastatic breast cancer and Imbruvica ibrutinib from AbbVie and Johnson & Johnson to treat chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Imbruvica had been added in December to the list of covered drugs. ...